Signal
Genetics Inc. (Nasdaq: SGNL) signed a Master Service Agreement with a leading
pharmaceutical to conduct multiple clinical trials using Signal's
MyPRS(R) genetic test to develop treatments for patients with multiple
myeloma. The stock price surged 89 cents to $2.37.
Signal Genetics signs Master Service Agreement
June 30, 2015 at 11:57 AM EDT
